The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.

Shram, M. J., Henningfield, J. E., Apseloff, G., Gorodetzky, C. W., De Martin, S., Vocci, F. L., Sapienza, F. L., Kosten, T. R., Huston, J., Buchhalter, A., Ashworth, J., Lanier, R., Folli, F., Mattarei, A., Guidetti, C., Comai, S., O’Gorman, C., Traversa, S., Inturrisi, C. E., Manfredi, P.L., Pappagallo, M. (2023). The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Transl Psychiatry, 13 (1), 192. https://doi.org/10.1038/s41398-023-02473-8.